BiotechTube
SuviCa

SuviCa

San Diego, United States· Est.
suvica.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.8M

Overview

SuviCa is a preclinical-stage oncology biotech developing small molecule protein synthesis inhibitors designed to overcome resistance to standard cancer treatments. The company's lead asset, SVC112, is in preclinical development and targets a unique mechanism to prevent tumor regrowth post-therapy. Led by an experienced management team with a strong track record in biotech, including CEO Judy Hemberger, PhD, MBA, SuviCa leverages academic research from its co-founder and CSO, Dr. Tin Tin Su. The company has secured non-dilutive funding through SBIR grants and is positioned to pursue combination therapy opportunities in oncology.

Oncology

Technology Platform

Proprietary whole-animal screening platform to identify small molecule protein synthesis inhibitors that target cancer cell recovery and regrowth following standard therapies (e.g., chemo, radiation).

Funding History

1
Total raised:$1.8M
Seed$1.8M

Opportunities

SuviCa's technology addresses the major unmet need of tumor recurrence and resistance, positioning its lead asset as a potential combination therapy partner for a wide range of existing oncology treatments.
Successful validation of its novel mechanism could create a new class of drugs with broad applicability across multiple solid tumor types.

Risk Factors

The company faces high translational risk as its novel, unproven mechanism moves from preclinical models to human trials.
As a preclinical, private company, it is dependent on securing significant future financing to advance into and through clinical development.

Competitive Landscape

The oncology therapeutics space is intensely competitive, dominated by large pharma and well-funded biotechs. While SuviCa's specific mechanism is unique, it competes indirectly with all companies developing adjuvant or resistance-overcoming therapies, including other protein synthesis inhibitors and novel targeted agents.

More companies in Small Molecule Drugs →More companies in United States →